id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_tpiqgspaqvfeng2fovbximt4lm	Alan R. Shuldiner	Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy	2009.0	10	.pdf	application/pdf	8775	1266	62	Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy Design, Setting, and Participants In the Pharmacogenomics of Antiplatelet Intervention (PAPI) Study (2006-2008), we administered clopidogrel for 7 days to 429 genome-wide association study was performed followed by genotyping the loss-offunction cytochrome P450 (CYP) 2C19*2 variant (rs4244285). Main Outcome Measure ADP-stimulated platelet aggregation in response to clopidogrel treatment and cardiovascular events. Conclusion CYP2C19*2 genotype was associated with diminished platelet response to clopidogrel treatment and poorer cardiovascular outcomes. platelet function in response to clopidogrel has been associated with lipophilic statins, calcium channel blockers, proton pump inhibitors, St John's antiplatelet effect19-23 and with increased cardiovascular events in patients receiving clopidogrel.18,24-26 Indeed, follow-up genotyping indicated that the common lossof-function CYP2C19*2 variant was associated with clopidogrel response and replication of the initial association between CYP2C19*2 genotype and clopidogrel response, the Baltimore Sinai We report the first genome-wide association study of clopidogrel response	./cache/work_tpiqgspaqvfeng2fovbximt4lm.pdf	./txt/work_tpiqgspaqvfeng2fovbximt4lm.txt